Identification of new NMOSD and MOGAD genetic associations
- Creators
- Vince, Nicolas
- Charles, Irène
- Bourguiba-Hachemi, Sonia
- Vukusic, Sandra
- Banyahya, Lakhdar
- Durand-Dubief, Françoise
- Cotton, François
- Zéphyr, Thi Hélène
- Maillart, Elisabeth
- Papeix, Caroline
- Audoin, Bertrand
- Ayrignac, Xavier
- Bourre, Bertrand
- Ciron, Jonathan
- Cohen, Mikael
- Collongues, Nicolas
- Deschamps, Romain
- Ruet, Aurélie
- Thouvenot, Eric
- Marignier, Romain
- Limou, Sophie
- Gourraud, Pierre-Antoine
- Laplaud, David‐axel
- Others:
- Centre de Recherche en Transplantation et Immunologie - Center for Research in Transplantation and Translational Immunology (U1064 Inserm - CR2TI) ; Institut National de la Santé et de la Recherche Médicale (INSERM)-Nantes Université - UFR de Médecine et des Techniques Médicales (Nantes Univ - UFR MEDECINE) ; Nantes Université - pôle Santé ; Nantes Université (Nantes Univ)-Nantes Université (Nantes Univ)-Nantes Université - pôle Santé ; Nantes Université (Nantes Univ)-Nantes Université (Nantes Univ)
- Centre de recherche en neurosciences de Lyon - Lyon Neuroscience Research Center (CRNL) ; Université Claude Bernard Lyon 1 (UCBL) ; Université de Lyon-Université de Lyon-Université Jean Monnet - Saint-Étienne (UJM)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)
- Service de Neurologie [Lyon] ; CHU Lyon
- Fondation Eugène Devic EDMUS
- Hôpital neurologique et neurochirurgical Pierre Wertheimer [CHU - HCL] ; Hospices Civils de Lyon (HCL)
- Centre Hospitalier Lyon Sud [CHU - HCL] (CHLS) ; Hospices Civils de Lyon (HCL)
- Centre de Recherche en Acquisition et Traitement de l'Image pour la Santé (CREATIS) ; Université Claude Bernard Lyon 1 (UCBL) ; Université de Lyon-Université de Lyon-Institut National des Sciences Appliquées de Lyon (INSA Lyon) ; Université de Lyon-Institut National des Sciences Appliquées (INSA)-Institut National des Sciences Appliquées (INSA)-Université Jean Monnet - Saint-Étienne (UJM)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)
- Lille Neurosciences & Cognition - U 1172 (LilNCog) ; Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Lille-Centre Hospitalier Régional Universitaire [CHU Lille] (CHRU Lille)
- Centre de Ressources et de Compétences sur la Sclérose en Plaques (CRC-SEP) [Lille] (CRC-SEP Nord-Pas de Calais)
- CHU Pitié-Salpêtrière [AP-HP] ; Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)
- Centre de Référence des Maladies Inflammatoires Rares du Cerveau et de la Moelle (MIRCEM)
- Hôpital Fondation Adolphe de Rothschild = Adolphe de Rothschild Foundation Hospital
- Institut de Neurosciences de la Timone (INT) ; Aix Marseille Université (AMU)-Centre National de la Recherche Scientifique (CNRS)
- Hôpital de la Timone [CHU - APHM] (TIMONE)
- Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier)
- Institut des Neurosciences de Montpellier (INM) ; Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Montpellier (UM)
- CHU Rouen ; Normandie Université (NU)
- Centre Ressources et Compétences sclérose en plaques (CRC-SEP) [CHU Toulouse] (CRC-SEP Toulouse) ; Département Neurologie [CHU Toulouse] ; Pôle Neurosciences [CHU Toulouse] ; Centre Hospitalier Universitaire de Toulouse (CHU Toulouse)-Centre Hospitalier Universitaire de Toulouse (CHU Toulouse)-Pôle Neurosciences [CHU Toulouse] ; Centre Hospitalier Universitaire de Toulouse (CHU Toulouse)-Centre Hospitalier Universitaire de Toulouse (CHU Toulouse)
- Centre Hospitalier Universitaire de Nice (CHU Nice)
- Unité de Recherche Clinique de la Côte d'Azur (URRIS UR2CA) ; Centre Hospitalier Universitaire de Nice (CHU Nice)-Université Côte d'Azur (UniCA)
- Service de Neurologie [Strasbourg] ; Centre Hospitalier Universitaire [Strasbourg] (CHU Strasbourg) ; Les Hôpitaux Universitaires de Strasbourg (HUS)-Les Hôpitaux Universitaires de Strasbourg (HUS)-Nouvel Hôpital Civil de Strasbourg ; Les Hôpitaux Universitaires de Strasbourg (HUS)
- CIC Strasbourg (Centre d'Investigation Clinique Plurithématique (CIC - P)) ; Université de Strasbourg (UNISTRA)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Nouvel Hôpital Civil de Strasbourg ; Les Hôpitaux Universitaires de Strasbourg (HUS)-Les Hôpitaux Universitaires de Strasbourg (HUS)-Hôpital de Hautepierre [Strasbourg]
- Neurocentre Magendie : Physiopathologie de la Plasticité Neuronale (U1215 Inserm - UB) ; Université de Bordeaux (UB)-Institut François Magendie-Institut National de la Santé et de la Recherche Médicale (INSERM)
- Service de neurologie [Bordeaux] ; CHU Bordeaux-Groupe hospitalier Pellegrin
- Institut de Génomique Fonctionnelle (IGF) ; Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-Université de Montpellier (UM)
- Service de Neurologie [CHU Nimes] (Pôle NIRR) ; Hôpital Universitaire Carémeau [Nîmes] (CHU Nîmes) ; Centre Hospitalier Universitaire de Nîmes (CHU Nîmes)-Centre Hospitalier Universitaire de Nîmes (CHU Nîmes)
- European Commmittee for Treatment and Research in Multiple Sclerosis (ECTRIMS)
- Americas Commmittee for Treatment and Research in Multiple Sclerosis (ACTRIMS)
Description
Introduction: Neuromyelitis Optica Spectrum Disorder (NMOSD) is a severe autoimmune demyelinating disease of the optic nerves and spinal cord affecting 0.4-4/100,000 individuals worldwide. Recently, an international consensus was reached to harmonize diagnosis criteria of neuroinflammatory diseases. The majority of patients with NMOSD are positive for a specific auto-antibody against the astrocytic aquaporin-4 (AQP4) water channel. A separate entity named MOGAD (MOG antibody-associated disease) groups patients with antibodies directed against the myelin oligodendrocyte glycoprotein (MOG). Two studies explored the genomic signature of NMOSD to date: 215 patients vs. 1244 controls from the USA and 203 patients vs. 1782 controls from Japan. They both found SNPs associated with NMOSD (AQP4) risk around HLA-DRB1 gene. However, only a few MOGAD patients were included in these GWASs, consequently, there is no formal GWAS about MOGAD to date.Objectives/Aims: To identify new genetic associations with NMOSD and MOGAD patients.Methods: DNA from 663 NMOSD and MOGAD patients (French NOMADMUS registry) was extracted and genotyped on the PMRA Affymetrix® Axiom chip (900k SNPs). After careful quality controls, we selected 656 patients with high-confidence genotypes.Results: We analyzed the genetic structure using a principal component analysis (PCA) to determine the ancestry of our patients. We could determine that a majority of our samples were of European ancestry (70%). We restricted our study to this population as other ancestries did not bear enough samples to perform a sufficiently powered analysis. We performed a GWAS comparing these patients to 1544 controls from France. We identified a SNP within the HLA class II genomic region to be significantly associated with NMOSD (AQP4) patients (P=1.1x10-9, OR 3.3) which is in line with previous studies. In addition, we found a novel SNP close to the MAP3K7 gene in chromosome 6 showing a suggestive association with MOGAD patients (P=3.9x10-7, OR 3.1).Conclusion: These preliminary results are very promising; however, additional analyses are needed to better describe these associations. We need to perform SNPs imputation to fine-map the genetic associations. We also need to impute the HLA to pinpoint associated HLA alleles, especially in NMOSD AQP4+ patients. This study is of great importance to better understand the genetic interplay between these neuroinflammatory diseases and find clues about their underlying pathophysiological mechanisms.
Abstract
International audience
Additional details
- URL
- https://hal.science/hal-04732129
- URN
- urn:oai:HAL:hal-04732129v1
- Origin repository
- UNICA